Annual CFF
-$6.32 M
-$1.47 M-30.34%
31 December 2023
Summary:
Anika Therapeutics annual cash flow from financing activities is currently -$6.32 million, with the most recent change of -$1.47 million (-30.34%) on 31 December 2023. During the last 3 years, it has fallen by -$2.55 million (-67.57%). ANIK annual CFF is now -135.73% below its all-time high of $17.70 million, reached on 31 December 1997.ANIK Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$3.99 M
-$2.88 M-259.23%
30 September 2024
Summary:
Anika Therapeutics quarterly cash flow from financing activities is currently -$3.99 million, with the most recent change of -$2.88 million (-259.23%) on 30 September 2024. Over the past year, it has dropped by -$3.88 million (-3528.18%). ANIK quarterly CFF is now -108.04% below its all-time high of $49.66 million, reached on 30 June 2020.ANIK Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$7.03 M
-$3.88 M-123.13%
30 September 2024
Summary:
Anika Therapeutics TTM cash flow from financing activities is currently -$7.03 million, with the most recent change of -$3.88 million (-123.13%) on 30 September 2024. Over the past year, it has dropped by -$1.03 million (-17.24%). ANIK TTM CFF is now -109.84% below its all-time high of $71.49 million, reached on 30 June 2020.ANIK TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ANIK Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -30.3% | -3528.2% | -17.2% |
| 3 y3 years | -67.6% | +42.8% | +79.9% |
| 5 y5 years | +78.1% | -118.4% | +17.0% |
ANIK Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -67.6% | +6.7% | -698.4% | +42.8% | -123.1% | +79.9% |
| 5 y | 5 years | -67.6% | +78.1% | -108.0% | +85.8% | -109.8% | +86.8% |
| alltime | all time | -135.7% | +78.1% | -108.0% | +86.7% | -109.8% | +86.8% |
Anika Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.99 M(+259.2%) | -$7.03 M(+123.1%) |
| June 2024 | - | -$1.11 M(-51.1%) | -$3.15 M(-54.9%) |
| Mar 2024 | - | -$2.27 M(-764.6%) | -$6.98 M(+10.4%) |
| Dec 2023 | -$6.32 M(+30.3%) | $342.00 K(-410.9%) | -$6.32 M(+5.4%) |
| Sept 2023 | - | -$110.00 K(-97.8%) | -$6.00 M(-42.9%) |
| June 2023 | - | -$4.94 M(+206.4%) | -$10.50 M(+87.4%) |
| Mar 2023 | - | -$1.61 M(-341.8%) | -$5.60 M(+15.5%) |
| Dec 2022 | -$4.85 M(-28.4%) | $667.00 K(-114.5%) | -$4.85 M(-11.1%) |
| Sept 2022 | - | -$4.61 M(>+9900.0%) | -$5.46 M(-30.3%) |
| June 2022 | - | -$46.00 K(-94.7%) | -$7.83 M(+8.9%) |
| Mar 2022 | - | -$862.00 K(-1536.7%) | -$7.19 M(+6.1%) |
| Dec 2021 | -$6.78 M(+79.6%) | $60.00 K(-100.9%) | -$6.78 M(-80.6%) |
| Sept 2021 | - | -$6.98 M(-1275.4%) | -$34.95 M(-34.2%) |
| June 2021 | - | $594.00 K(-231.7%) | -$53.15 M(+1201.4%) |
| Mar 2021 | - | -$451.00 K(-98.4%) | -$4.08 M(+8.2%) |
| Dec 2020 | -$3.77 M(-53.6%) | -$28.11 M(+11.6%) | -$3.77 M(-115.3%) |
| Sept 2020 | - | -$25.18 M(-150.7%) | $24.62 M(-65.6%) |
| June 2020 | - | $49.66 M(<-9900.0%) | $71.49 M(-975.7%) |
| Mar 2020 | - | -$141.00 K(-150.7%) | -$8.16 M(+0.3%) |
| Dec 2019 | -$8.14 M(-71.8%) | $278.00 K(-98.7%) | -$8.14 M(-3.9%) |
| Sept 2019 | - | $21.70 M(-172.3%) | -$8.47 M(-71.9%) |
| June 2019 | - | -$30.00 M(>+9900.0%) | -$30.17 M(+8.5%) |
| Mar 2019 | - | -$119.00 K(+116.4%) | -$27.80 M(-3.8%) |
| Dec 2018 | -$28.90 M(-9305.1%) | -$55.00 K(<-9900.0%) | -$28.90 M(+0.2%) |
| Sept 2018 | - | $0.00(-100.0%) | -$28.84 M(+0.4%) |
| June 2018 | - | -$27.63 M(+2158.9%) | -$28.74 M(+2925.7%) |
| Mar 2018 | - | -$1.22 M(<-9900.0%) | -$950.00 K(-402.5%) |
| Dec 2017 | $314.00 K(-101.3%) | $4000.00(-96.0%) | $314.00 K(-4.6%) |
| Sept 2017 | - | $101.00 K(-39.9%) | $329.00 K(+11.9%) |
| June 2017 | - | $168.00 K(+309.8%) | $294.00 K(-22.6%) |
| Mar 2017 | - | $41.00 K(+115.8%) | $380.00 K(-101.6%) |
| Dec 2016 | -$23.99 M(-2334.0%) | $19.00 K(-71.2%) | -$23.99 M(-3.6%) |
| Sept 2016 | - | $66.00 K(-74.0%) | -$24.89 M(-0.1%) |
| June 2016 | - | $254.00 K(-101.0%) | -$24.91 M(-1.0%) |
| Mar 2016 | - | -$24.33 M(+2671.3%) | -$25.16 M(-2442.3%) |
| Dec 2015 | $1.07 M(-79.9%) | -$878.00 K(-1891.8%) | $1.07 M(-64.4%) |
| Sept 2015 | - | $49.00 K(+880.0%) | $3.02 M(+3.5%) |
| June 2015 | - | $5000.00(-99.7%) | $2.91 M(+68.8%) |
| Mar 2015 | - | $1.90 M(+78.2%) | $1.73 M(-67.6%) |
| Dec 2014 | $5.33 M(-193.7%) | $1.06 M(-2075.7%) | $5.33 M(-236.1%) |
| Sept 2014 | - | -$53.90 K(-95.4%) | -$3.92 M(+130.1%) |
| June 2014 | - | -$1.18 M(-121.5%) | -$1.70 M(+79.9%) |
| Mar 2014 | - | $5.50 M(-167.2%) | -$946.60 K(-83.4%) |
| Dec 2013 | -$5.69 M(+649.6%) | -$8.19 M(-478.7%) | -$5.69 M(-364.6%) |
| Sept 2013 | - | $2.16 M(-607.1%) | $2.15 M(-1359.3%) |
| June 2013 | - | -$426.20 K(-156.0%) | -$170.70 K(+61.2%) |
| Mar 2013 | - | $761.70 K(-319.3%) | -$105.90 K(-86.0%) |
| Dec 2012 | -$758.90 K(-34.9%) | -$347.30 K(+118.6%) | -$758.90 K(+43.5%) |
| Sept 2012 | - | -$158.90 K(-56.0%) | -$528.70 K(-31.3%) |
| June 2012 | - | -$361.40 K(-432.5%) | -$769.80 K(+12.3%) |
| Mar 2012 | - | $108.70 K(-192.8%) | -$685.60 K(-41.2%) |
| Dec 2011 | -$1.17 M(-12.9%) | -$117.10 K(-70.7%) | -$1.17 M(-15.7%) |
| Sept 2011 | - | -$400.00 K(+44.3%) | -$1.38 M(0.0%) |
| June 2011 | - | -$277.20 K(-25.3%) | -$1.38 M(-6.8%) |
| Mar 2011 | - | -$371.10 K(+10.9%) | -$1.48 M(+11.0%) |
| Dec 2010 | -$1.34 M(-18.6%) | -$334.60 K(-16.4%) | -$1.34 M(-9.4%) |
| Sept 2010 | - | -$400.00 K(+5.6%) | -$1.48 M(+1.6%) |
| June 2010 | - | -$378.70 K(+69.0%) | -$1.45 M(-1.0%) |
| Mar 2010 | - | -$224.10 K(-52.7%) | -$1.47 M(-10.7%) |
| Dec 2009 | -$1.64 M(-109.8%) | -$474.00 K(+25.8%) | -$1.64 M(-123.8%) |
| Sept 2009 | - | -$376.80 K(-4.0%) | $6.90 M(-5.2%) |
| June 2009 | - | -$392.70 K(-1.8%) | $7.28 M(-37.4%) |
| Mar 2009 | - | -$400.00 K(-105.0%) | $11.62 M(-30.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2008 | $16.69 M(+560.6%) | $8.07 M(>+9900.0%) | $16.69 M(+85.2%) |
| Sept 2008 | - | $0.00(-100.0%) | $9.01 M(-3.5%) |
| June 2008 | - | $3.96 M(-15.2%) | $9.34 M(+41.5%) |
| Mar 2008 | - | $4.66 M(+1090.7%) | $6.60 M(+161.4%) |
| Dec 2007 | $2.53 M(+46.4%) | $391.70 K(+18.3%) | $2.53 M(+3.6%) |
| Sept 2007 | - | $331.20 K(-72.8%) | $2.44 M(-11.0%) |
| June 2007 | - | $1.22 M(+107.6%) | $2.74 M(+55.9%) |
| Mar 2007 | - | $586.10 K(+93.1%) | $1.76 M(+1.8%) |
| Dec 2006 | $1.73 M(+210.2%) | $303.50 K(-51.9%) | $1.73 M(+17.7%) |
| Sept 2006 | - | $631.40 K(+168.2%) | $1.47 M(+73.6%) |
| June 2006 | - | $235.40 K(-57.6%) | $844.70 K(-13.5%) |
| Mar 2006 | - | $555.10 K(+1153.0%) | $977.00 K(+75.7%) |
| Dec 2005 | $556.20 K(-3.8%) | $44.30 K(+347.5%) | $556.20 K(-20.6%) |
| Sept 2005 | - | $9900.00(-97.3%) | $700.10 K(-18.4%) |
| June 2005 | - | $367.70 K(+173.8%) | $858.20 K(+21.5%) |
| Mar 2005 | - | $134.30 K(-28.6%) | $706.50 K(+22.2%) |
| Dec 2004 | $578.20 K(+521.7%) | $188.20 K(+12.0%) | $578.20 K(+38.0%) |
| Sept 2004 | - | $168.00 K(-22.2%) | $419.00 K(+36.9%) |
| June 2004 | - | $216.00 K(+3500.0%) | $306.00 K(+209.1%) |
| Mar 2004 | - | $6000.00(-79.3%) | $99.00 K(+6.5%) |
| Dec 2003 | $93.00 K(>+9900.0%) | $29.00 K(-47.3%) | $93.00 K(+45.3%) |
| Sept 2003 | - | $55.00 K(+511.1%) | $64.00 K(+611.1%) |
| June 2003 | - | $9000.00(>+9900.0%) | $9000.00(>+9900.0%) |
| Mar 2003 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2002 | $0.00(0.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2002 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2002 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2002 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2001 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2001 | - | $0.00(0.0%) | $0.00(-100.0%) |
| June 2001 | - | $0.00(0.0%) | $44.50 K(-90.0%) |
| Mar 2001 | - | $0.00(0.0%) | $444.30 K(-17.7%) |
| Dec 2000 | $539.90 K(-137.7%) | $0.00(-100.0%) | $539.90 K(+6.4%) |
| Sept 2000 | - | $44.50 K(-88.9%) | $507.30 K(+9.6%) |
| June 2000 | - | $399.80 K(+318.2%) | $462.80 K(-17.8%) |
| Mar 2000 | - | $95.60 K(-393.3%) | $563.00 K(-139.3%) |
| Dec 1999 | -$1.43 M(+43.3%) | -$32.60 K(<-9900.0%) | -$1.43 M(-55.2%) |
| Sept 1999 | - | $0.00(-100.0%) | -$3.20 M(-3.0%) |
| June 1999 | - | $500.00 K(-126.3%) | -$3.30 M(-10.8%) |
| Mar 1999 | - | -$1.90 M(+5.6%) | -$3.70 M(+270.0%) |
| Dec 1998 | -$1.00 M(-105.6%) | -$1.80 M(+1700.0%) | -$1.00 M(-105.6%) |
| Sept 1998 | - | -$100.00 K(-200.0%) | $18.00 M(-1.6%) |
| June 1998 | - | $100.00 K(-87.5%) | $18.30 M(0.0%) |
| Mar 1998 | - | $800.00 K(-95.3%) | $18.30 M(+3.4%) |
| Dec 1997 | $17.70 M(+8750.0%) | $17.20 M(+8500.0%) | $17.70 M(+2428.6%) |
| Sept 1997 | - | $200.00 K(+100.0%) | $700.00 K(-12.5%) |
| June 1997 | - | $100.00 K(-50.0%) | $800.00 K(-75.8%) |
| Mar 1997 | - | $200.00 K(0.0%) | $3.30 M(+6.5%) |
| Dec 1996 | $200.00 K(-93.1%) | - | - |
| Nov 1996 | - | $200.00 K(-33.3%) | $3.10 M(+6.9%) |
| Aug 1996 | - | $300.00 K(-88.5%) | $2.90 M(+11.5%) |
| Aug 1996 | $2.90 M(+26.1%) | - | - |
| May 1996 | - | $2.60 M(>+9900.0%) | $2.60 M(+13.0%) |
| Feb 1996 | - | $0.00(0.0%) | $2.30 M(0.0%) |
| Nov 1995 | - | $0.00(0.0%) | $2.30 M(0.0%) |
| Aug 1995 | $2.30 M(+2200.0%) | $0.00(-100.0%) | $2.30 M(0.0%) |
| May 1995 | - | $2.30 M(>+9900.0%) | $2.30 M(+2200.0%) |
| Feb 1995 | - | $0.00(0.0%) | $100.00 K(0.0%) |
| Nov 1994 | - | $0.00(0.0%) | $100.00 K(0.0%) |
| Aug 1994 | $100.00 K(-98.6%) | $0.00(-100.0%) | $100.00 K(0.0%) |
| May 1994 | - | $100.00 K(>+9900.0%) | $100.00 K(>+9900.0%) |
| Feb 1994 | - | $0.00(0.0%) | $0.00(0.0%) |
| Nov 1993 | - | $0.00 | $0.00 |
| Aug 1993 | $6.90 M | - | - |
FAQ
- What is Anika Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Anika Therapeutics?
- What is Anika Therapeutics annual CFF year-on-year change?
- What is Anika Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Anika Therapeutics?
- What is Anika Therapeutics quarterly CFF year-on-year change?
- What is Anika Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Anika Therapeutics?
- What is Anika Therapeutics TTM CFF year-on-year change?
What is Anika Therapeutics annual cash flow from financing activities?
The current annual CFF of ANIK is -$6.32 M
What is the all time high annual CFF for Anika Therapeutics?
Anika Therapeutics all-time high annual cash flow from financing activities is $17.70 M
What is Anika Therapeutics annual CFF year-on-year change?
Over the past year, ANIK annual cash flow from financing activities has changed by -$1.47 M (-30.34%)
What is Anika Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ANIK is -$3.99 M
What is the all time high quarterly CFF for Anika Therapeutics?
Anika Therapeutics all-time high quarterly cash flow from financing activities is $49.66 M
What is Anika Therapeutics quarterly CFF year-on-year change?
Over the past year, ANIK quarterly cash flow from financing activities has changed by -$3.88 M (-3528.18%)
What is Anika Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ANIK is -$7.03 M
What is the all time high TTM CFF for Anika Therapeutics?
Anika Therapeutics all-time high TTM cash flow from financing activities is $71.49 M
What is Anika Therapeutics TTM CFF year-on-year change?
Over the past year, ANIK TTM cash flow from financing activities has changed by -$1.03 M (-17.24%)